🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A cohort comparison study of >100,000s patients reassures us that semaglutide is not associated with ophthalmic complication of NAION 👉ajo.com/article/S0002-… In T2D, semaglutide vs non-GLP1 controls (n=130,000): 1-year RR 1.000, 95% CI 0.652-1.534 3-year RR 0.840,

cjcopen.ca/action/doSearc… Artur Dziewierz

#Gigerl Stadtheuriger #Vienna

#Gigerl Stadtheuriger #Vienna

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

So much exciting news from #ADA2025

This is a very good review of type 2 diabetes jamanetwork.com/journals/jama/…

121 years ago Today, Marie Skłodowska Curie went before the examination committee for her Ph.D., becoming the first woman in France to receive a doctoral degree. Later in this same year she was awarded a Nobel Prize for her research.

2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology DOI: 10.1016/j.jacc.2025.05.008 Contributed by Baim CSO: Dr. James L. Januzzi 👏 #Cardiology

Summary of REDEFINE 1 and REDEFINE 2 trials with CagriSema, presented this week at #ADA2025 and published in NEJM: REDEFINE 1: • 👥 3,417 participants with obesity or overweight (without diabetes) treated with CagriSema achieved a 22.7% weight loss after 68 weeks, compared to

Mediocre results from the Phase 3a trial for cagrilintide and semaglutide #CagriSema in obesity and type 2 diabetes. Average weight loss at week 68 was -13.7% in the CagriSema group and -3.4% in the placebo group. www-nejm-org.proxy.library.emory.edu/doi/10.1056/NE…

53y F. 6m ago atypical chest pain. Stable persistant V2-V4 ST depressions. ExT EKG positive with no pain. In angoiCT 70% mid LAD. In CAG 50% SCAD in LAD. Conservative Tx. Now similar symptoms. Trop neg. What next? Mamas A. Mamas Hany Ragy Cian McCarthy Piotr Buszman MD, PhD Giuseppe Biondi-Zoccai

GLP-1 receptor agonist usage is associated with decreased risk of lower extremity amputations, diabetic foot ulcers, and mortality compared to SGLT2 inhibitors in people with type 2 diabetes. ADA Professional Publications Read Here➡️ diabetesjournals.org/care/lookup/do…

🔍 New Data: BMI May Miss Millions with Clinical Obesity via Jackie Yao and colleagues - - - A landmark study of 249,000 U.S. adults tested a new way to define obesity—and the results are eye-opening. 🧬 Using clinical definition of obesity (not just BMI ≥30), researchers

I would like to thank Mamas A. Mamas Cian McCarthy and Davide Capodanno for providing peer support for my US immigrant visa petition. I just learned that I got approved also on the basis of strong letters of recommendation from outstanding faculty !

Jest w akademii takie myślenie, że na ujawnienie się talentu naukowego czasem trzeba poczekać. Że jak ktoś jest słabym badaczem, to trzeba dać czas i ciepły etacik, bo może za 15 lat talent eksploduje. No więc najnowsze badania M. Kwieka i Ł. Szymuli pokazują, że to bajki.

Do dyskusji. Przedluzamy program KOS-BAR i słusznie. Ale to raptem 10 tys procedur rocznie. Ograniczone do kilkunastu osrodkow. W ciagu 10 lat pomozemy 100 tys pacjentów. Do leczenia otylosci kwalifikuje się w Polsce...kilka milionów. Michał Chudzik Piotr Jankowski Małgorzata Gałązka -Sobotka

My latest opus is finally online: Medical Statistics: A User-Friendly Handbook amazon.it/statistics-Use…